← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Portland Va Research Foundation, Inc.
Portland, OR
$10,917,379
Total funding
16
Grants
Funding over time
peak $3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$8,658,847 · 7
NIH$2,258,532 · 9
By mechanism
—$8,658,847 · 7
R01$1,066,000 · 1
T35$447,840 · 1
G20$447,470 · 1
R13$297,222 · 6
Investigators at Portland Va Research Foundation, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
PRECLINICAL DEVELOPMENT OF NOVEL LIVER-STAGE ACTIVE ANTIMALARIALS WITH RADICAL CURE POTENTIAL$2,876,922
· FY2022 · Department of the Army
FORMULATION DEVELOPMENT OF A NEW ANTIMALARIAL PRECLINICAL CANDIDATE ELQ-300 AND PRODRUGS$1,621,780
· FY2014 · Department of Defense
NOVEL LIVER-STAGE-ACTIVE ANTIMALARIALS$1,238,280
· FY2017 · Department of the Army
GLIMPSE-PD: GLYMPHATICS IMAGING TO PROBE SLEEP IN PARKINSON'S DISEASE$1,047,751
· FY2024 · Defense Health Agency
MOLECULAR CHANGES ASSOCIATED WITH INITIAL STEPS OF BREAST CANCER METASTASIS FOR RISK STRATIFICATION AND THERAPY DEVELOPMENT$674,547
· FY2016 · Department of the Army
POLYGENIC RISK SCORES PRS TO PREDICT POST TRAUMATIC EPILEPSY PTE IN THE MILLION VETERAN PROGRAM MVP COHORT$614,140
· FY2025 · Defense Health Agency
NOVEL SYNERGISTIC ANTIMALARIALS WITH GAMETOCYTOCIDAL ACTIVITY$585,427
· FY2015 · Department of Defense
Purchase of Ventilated Caging Systems and Workstations$447,470
G20 · FY2006 · RR
Genetic Pathways of Human Cytomegalovirus Drug Resistance$312,000
R01 · FY2024 · AI
Genetic Pathways of Human Cytomegalovirus Drug Resistance$312,000
R01 · FY2023 · AI
Genetic Pathways of Human Cytomegalovirus Drug Resistance$312,000
R01 · FY2025 · AI
Genetic Pathways of Human Cytomegalovirus Drug Resistance$130,000
R01 · FY2022 · AI
DOPAMINE 2002$47,000
R13 · FY2002 · DA
The Biennial VA NCRAR Scientific Conference Series$39,875
R13 · FY2021 · DC
The Biennial VA NCRAR Scientific Conference Series$39,731
R13 · FY2023 · DC
Ototoxicity and Noise Damage: Translating Preclinical Findings to Audiological Management$38,903
R13 · FY2019 · DC
The Biennial VA NCRAR Scientific Conference Series$36,659
R13 · FY2025 · DC
Translating Tinnitus Research Findings into Clinical Practice$35,072
R13 · FY2017 · DC
Hearing Loss as a Public Health Concern$34,431
R13 · FY2015 · DC
Ruth L. Kirschstein NRSA Short-Term Institutional Research Training Grant (T35)$33,212
T35 · FY2022 · DC